regulatory
confidence high
sentiment negative
materiality 0.75
Aptevo receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Dec 23, 2024
Aptevo Therapeutics Inc.
- Received Nasdaq Staff letter on June 25, 2024, for failure to meet minimum $1.00 bid price requirement.
- Has 180 calendar days, until December 23, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If noncompliant by Dec 23, may be eligible for additional 180-day period if meets other listing standards and intends to cure via reverse stock split.
- Failure to regain compliance could result in delisting; company will monitor and evaluate options.